Oslo, 10 February 2023 - Observe Medical ASA ("the Company" or "Observe
Medical") will release its fourth quarter 2022 results on Friday, 17 February
2023. The presentation will be made available on NewsWeb and the Company's
website at 07:00 CET on the same day.

Rune Nystad, CEO, and Per Arne Nygård, CFO, will host a presentation and
Q&A session at 08:30 CET on the day of the results. The presentation will take
place at Haakon VIIs gate 2 and will be available via webcast at the following
link: https://channel.royalcast.com/landingpage/hegnarmedia/20230217_3/

After the live event, the presentation and recording will be made
available under the Investor Relations section on the Company's website,

https://observemedical.com/investor-relations/.

For further information, please contact:


Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

About Observe Medical


Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A. The Company is headquartered in Oslo, Norway,
with additional offices in Narvik (Norway), Gothenburg (Sweden), Oulu (Finland),
and Seattle (the US). In addition, Observe Medical has a direct sale
organisation in the Nordics and a distributor network internationally.

Further information is available at www.observemedical.com.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange